Today, The Panic-Proof Portfolio (Stockchase Research) and Lorne Steinberg commented about whether NSRGY-OTC, CVS-N, ALL-N, ADBE-Q, TSM-N, TRP-T, RY-T, SNN-N, V-N, AC-T, JPM-N, VTRS-Q, PPRUY-OTC, KVUE-N, CM-T, SNE-N, PFE-N, BCE-T, BN-T, NVO-N, MFC-T, BDX-N, UBER-N, MDT-N, MRK-N, TRDA-Q, GSY-T, ONIT-N, CMCSA-Q, RPRX-Q are stocks to buy or sell.
There's value outside North America as the valuation gap between US stocks and ex-US wider than ever. Add to that the strong USD, so those foreign companies are cheap. He likes Japan, UK, and Europe, though many do business in the US. 2025 Canadian outlook: bullish because of further interest rate cuts, and Canada is dividend-driven.
No, you can never do that. Remember that MFC plunged during 2008 because it got into all kinds of trouble. Today, management has learned a lot from that. He sees big upside in their insurance, US and Asian operations. Still offers decent value and dividend growth. However, insurance companies are prone to serious slides if they make a bad misjudgement.
He won't add now. The dividend is over 10%; the company says it's safe, but the market disagrees, as shares decline. It may make sense for BCE to cut the dividend to pay down debt, but he's comfortable owning this. It's likely bottoming now, but don't buy it now to collect the dividend for the next 5 years (because it could get cut). No, he doesn't like the US acquisition and hopes management sees value in it.
RPRX partners with pharma companies like Bristol-Myers to help fund development in exchange for collecting royalties. It pays a good dividend, backed by a payout ratio under 33% of cash flow. It trades at 10x earnings, under 2x book and supports a 17% ROE. Its portfolio grew by 15% this year. We recommend setting a stop-loss at $22, looking to achieve $33 -- upside potential of 28%. Yield 3.2%
(Analysts’ price target is $41.53)